Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

RXi Pharmaceuticals Corp RXII

Healthcare Biotechnology
"RXi Pharmaceuticals Corp is a clinical-stage RNAi company developing therapeutics based on its proprietary self-delivering RNAi platform and Samcyprone, a topical immunomodulator, which address significant unmet medical needs."


NDAQ:RXII - Post by User

RXi Pharmaceuticals Corp > RXIIW warrant selling at steep steep discount to true market
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(0)
•••
Comment by SimArchitecton Feb 08, 2017 11:14pm
145 Views
Post# 25820727

RE:RXIIW warrant selling at steep steep discount to true market

RE:RXIIW warrant selling at steep steep discount to true market
OMG! I thought I was crazy about those warrants! Thanks for sharing your analysis, I am also 100% bought in!
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities